NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: In Vitro & In Vivo Diagnostic Substances
www.lantheus.comLantheus plans to file a New Drug Application for MK-6240, a tau PET radiodiagnostic, with the FDA in Q3 2025, following successful pivotal study results.
fda decisionLantheus Holdings has entered a definitive agreement to sell its SPECT (single photon emission computed tomography) business, including diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite, to SHINE Technologies. The transaction includes related manufacturing facilities and Canadian operations, and is expected to close by year-end 2025, subject to customary conditions. Lantheus will receive upfront cash, a convertible note, and potential earnouts. The divestiture will allow Lantheus to focus on PET radiodiagnostics and its radiopharmaceutical pipeline, while SHINE expands its nuclear medicine platform. SPECT products are used for diagnostic imaging in cardiology and neurology.
merger close